ReviewDiagnostics (Basel, Switzerland)2022
A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Hidden Burden of Depression in STEMI: Effects on Early Complications and 12-Month MACCE.Diagnostics (Basel, Switzerland) · 2026Article
- A single-center observational study on the impact of intravascular ultrasound-detected attenuated plaque on coronary microvascular dysfunction following percutaneous coronary intervention.The international journal of cardiovascular imaging · 2026Observational
- Complete Revascularization in NSTE-ACS and Multivessel Disease: Clinical Outcomes and Prognostic Implications.Life (Basel, Switzerland) · 2025Article
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker.Medical sciences (Basel, Switzerland) · 2025Article
- Exploring the Intersection of Geophysics and Diagnostic Imaging in the Health Sciences.Diagnostics (Basel, Switzerland) · 2024Review
- Lipidomic Predictors of Coronary No-Reflow.Metabolites · 2023Article
- Hemorheological and Microcirculatory Relations of Acute Pancreatitis.Metabolites · 2022Review
- Myocardial Viability Testing in the Management of Ischemic Heart Failure.Life (Basel, Switzerland) · 2022Review
- Usefulness of the Edmonton Frail Scale in Assessing the Impact of Heart Failure on Frailty.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of the no-reflow (NR) phenomenon varies depending on the diagnostic criteria used. If just the angiographic criteria are considered (i.e., a degree of thrombolysis in myocardial infarction ≤2), it will be found that the incidence of NR is quite low; on the other hand, when the myocardial NR is taken into account (i.e., a decrease in the quality of myocardial reperfusion expressed by the degree of myocardial blush), the real incidence is higher. Thus, the early establishment of a diagnosis of NR and the administration of specific treatment can lead to its reversibility. Otherwise, regardless of the follow-up period, patients with NR have a poor prognosis. In the present work, we offer a comprehensive perspective on diagnostic tools for NR detection, for improving the global management of patients with arterial microvasculature damage, which is a topic of major interest in the cardiology field, due to its complexity and its link with severe clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.